Isabelle Desombere

Isabelle Desombere

Auto-generated profile, based on publicly available information

Isabelle Desombere

Department of Infectious Diseases in Humans, Sciensano, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2021 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
LBLise Boey
Lise Boey
MRMathieu Roelants
Mathieu Roelants
JMJoanna Merckx
Joanna Merckx
NHNiel Hens
Niel Hens
IDIsabelle Desombere
Isabelle Desombere
CVCorinne Vandermeulen
Corinne Vandermeulen

10 February 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
DKDelphine Kemlin
Delphine Kemlin
NGNicolas Gemander
Nicolas Gemander
SDStéphanie Depickère
Stéphanie Depickère
VOVéronique Olislagers
Véronique Olislagers
DGDaphnée Georges
Daphnée Georges
AMArnaud Marchant
Arnaud Marchant
As solid organ transplant recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been identified in this vulnerable population. We conducted a prospective monocentric cohort study of 65 kidney transplant recipients who received 3 doses of BNT162b2 mRNA vaccine. Associations among breakthrough infection (BTI), vaccine responses, and patient characteristics were explored in 54 patients. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of 6 months after booster vaccination. During this period, SARS-CoV-2 delta and omicron were the dominant variants in the general population. Univariate Analyses identified the avidity of SARS-CoV-2 receptor binding domain binding IgG, neutralizing antibodies, and SARS-CoV-2 S2-specific interferon gamma responses as correlates of protection against BTI. No demographic or clinical parameter correlated with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing antibody and S2-specific interferon gamma responses. In conclusion, T cell responses may help compensate for the suboptimal antibody response to booster vaccination in kidney transplant recipients. Further studies are needed to confirm these findings.

1 December 2017 in Antiviral Research
Verified
Journal Article
Open access
IDIsabelle Desombere
Isabelle Desombere
AMAhmed Atef Mesalam
Ahmed Atef Mesalam
RURichard A. Urbanowicz
Richard A. Urbanowicz
FHFreya Van Houtte
Freya Van Houtte
LVLieven Verhoye
Lieven Verhoye
PMPhilip Meuleman
Philip Meuleman
Infections with hepatitis C virus (HCV) represent a worldwide health burden and a prophylactic vaccine is still not available. Liver transplantation (LT) is often the only option for patients with HCV-induced end-stage liver disease. However, immediately after transplantation, the liver graft becomes infected by circulating virus, resulting in accelerated progression of liver disease. Although the efficacy of HCV treatment using direct-acting antivirals has improved significantly, immune compromised LT-patients and patients with advanced liver disease remain difficult to treat. As an alternative approach, interfering with viral entry could prevent infection of the donor liver. We generated a human monoclonal antibody (mAb), designated 2A5, which targets the HCV envelope. The neutralizing activity of mAb 2A5 was assessed using multiple prototype and patient-derived HCV pseudoparticles (HCVpp), cell culture produced HCV (HCVcc), and a human-liver chimeric mouse model. Neutralization levels observed for mAb 2A5 were generally high and mostly superior to those obtained with AP33, a well-characterized HCV-neutralizing monoclonal antibody. Using humanized mice, complete protection was observed after genotype 1a and 4a HCV challenge, while only partial protection was achieved using gt1b and 6a isolates. Epitope mapping revealed that mAb 2A5 binding is conformation-dependent and identified the E2-region spanning amino acids 434 to 446 (epitope II) as the predominant contact domain. mAb 2A5 shows potent anti-HCV neutralizing activity both in vitro and in vivo and could hence represent a valuable candidate to prevent HCV recurrence in LT-patients. In addition, the detailed identification of the neutralizing epitope can be applied for the design of prophylactic HCV vaccines.

1 October 2019 in Journal of Medical Microbiology
Verified
Journal Article
Closed access
HMHelena Martini
Helena Martini
OSOriane Soetens
Oriane Soetens
DLDavid Litt
David Litt
NFNorman Fry
Norman Fry
LDLiselot Detemmerman
Liselot Detemmerman
DPDenis Pierard
Denis Pierard
In Western Europe, the incidence of both respiratory and cutaneous diphtheria, caused by toxin-producing Corynebacterium diphtheriae, Corynebacterium ulcerans or Corynebacterium pseudotuberculosis, has been low over the past few decades thanks to the use of an effective vaccine and a high level of vaccination coverage. However, the disease has still not been eradicated and continues to occur in all of Europe. In order to prevent sequelae or a fatal outcome, diphtheria antitoxin (DAT) should be administered to suspected diphtheria patients as soon as possible, but economic factors and issues concerning regulations have led to poor availability of DAT in many countries. The European Centre for Disease Prevention and Control and World Health Organization have called for European Union-wide solutions to this DAT-shortage. In order to illustrate the importance of these efforts and underline the need for continued diphtheria surveillance, we present data on all registered cases of toxigenic and non-toxigenic C. diphtheriae, C. ulcerans and C. pseudotuberculosis in Belgium during the past decade, up to and including 2017.

4 January 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
LBLise Boey
Lise Boey
EBEline Bosmans
Eline Bosmans
LFLiane Braz Ferreira
Liane Braz Ferreira
NHNathalie Heyvaert
Nathalie Heyvaert
MNMelissa Nelen
Melissa Nelen
CVCorinne Vandermeulen
Corinne Vandermeulen
Patients with chronic diseases are at increased risk of complications following infection. It remains, however, unknown to what extend they are protected against vaccine-preventable diseases. We assessed seroprevalence of antibodies against diphtheria, tetanus and pertussis to evaluate whether current vaccination programs in Belgium are adequate. Antibody titers were assessed with a bead-based multiplex assay in serum of 1052 adults with chronic diseases. We included patients with diabetes mellitus type 1 (DM1) (n = 172), DM2 (n = 77), chronic kidney disease (n = 130), chronic obstructive pulmonary disease (COPD) (n = 170), heart failure (n = 77), HIV (n = 196) and solid organ transplant (SOT) recipients (n = 230). Factors associated with seroprevalence were analysed with multiple logistic regression. We found seroprotective titers in 29% for diphtheria (≥0.1 IU/mL), in 83% for tetanus (≥0.1 IU/mL) and 22% had antibodies against pertussis (≥5 IU/mL). Seroprotection rates were higher (p < 0.001) when vaccinated within the last ten years. Furthermore, diphtheria seroprotection decreased with age (p < 0.001). Tetanus seroprotection was less reached in women (p < 0.001) and older age groups (p < 0.001). For pertussis, women had more often a titer suggestive of a recent infection or vaccination (≥100 IU/mL, p < 0.01). We conclude that except for tetanus, the vast majority of at-risk patients remains susceptible to vaccine-preventable diseases such as diphtheria and pertussis.

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
DKDelphine Kemlin
Delphine Kemlin
ALAnne Lemy
Anne Lemy
PPPieter Pannus
Pieter Pannus
IDIsabelle Desombere
Isabelle Desombere
NGNicolas Gemander
Nicolas Gemander
AMAlain Le Moine
Alain Le Moine